The guidelines moved on. Most of us haven’t. Should we?

Abstract

TL;DR The 12%/200 mL bronchodilator reversibility rule no longer holds up. A layered model replaces it: post-bronchodilator obstruction confirms disease, etiotype clarifies cause, and treatable traits and endotypes (type 2 vs NOD-like receptor pyrin domain-containing 3 [NLRP3]) direct therapy.

The bronchodilator reversibility (BDR) criterion of a 12% and 200 mL improvement in forced expiratory volume in 1 second (FEV1) has anchored the diagnostic workup of asthma and COPD for three decades. Contemporary evidence shows that this threshold is nondiscriminating, irreproducible, and nonpredictive of treatment response. The 2025 Global Initiative for Chronic Obstructive Lung Disease (GOLD) report has formally removed reversibility from the COPD diagnostic algorithm, and the 2024 Global Initiative for Asthma (GINA) update has progressively softened its role in asthma. The replacement is not a single new test. It is a layered model in which postbronchodilator obstruction confirms disease, etiotype clarifies cause, and treatable traits and endotypes direct therapy. Within this model, the NLRP3 inflammasome and the type 2 (T2) cytokine axis define the two principal injury-type endotypes that determine biologic eligibility. We synthesize the academic literature, enumerate the arguments on both sides, propose a step-by-step diagnostic algorithm that reconciles GOLD 2025 with GINA 2024, and outline how the NOVELTY and UPLIFT cohorts together demolish the diagnostic use of the legacy BDR rule.

1. Why the 12% / 200 mL Rule Is Failing

TL;DR In UPLIFT, 54% to 73% of patients with confirmed COPD met the BDR criterion. NOVELTY showed it does not separate asthma from COPD. EMAX showed it does not predict treatment response. GOLD 2025 and American Thoracic Society (ATS)/European Respiratory Society (ERS) 2022 have already demoted it. Counterarguments exist, but the honest synthesis is demotion, not deletion.

The conceptual debt of the legacy BDR threshold is that it was asked to do three jobs simultaneously: discriminate asthma from COPD, predict response to bronchodilator therapy, and gate the diagnosis itself. The empirical evidence base no longer supports any of these uses. In the UPLIFT cohort of 5,756 patients with established COPD, 54% met the 12% plus 200 mL criterion and 73% met the 12% criterion alone over 4 years of standardized testing.1,3 In the NOVELTY cohort (n=9,180), reversibility status failed to differentiate physician-diagnosed asthma from COPD.2 Post-hoc analysis of EMAX showed that pretreatment BDR did not predict subsequent long-acting muscarinic antagonist (LABA)/long-acting beta-agonist (LAMA) response in COPD.4 The 2022 ERS/ATS technical standard accordingly replaced the 12%/200 mL definition with a 10%-predicted criterion to eliminate height, sex, and age bias,8 and the 2025 GOLD report removed reversibility from the diagnostic algorithm while retaining postbronchodilator FEV1/forced vitality capacity (FVC) less than 0.7 as the obstruction gate.5,6 GINA 2024 has likewise softened reversibility, particularly in primary care.7

Counterarguments retain force. BDR remains useful in steroid-naive adults with equivocal symptoms,26 and a large response of at least 20% carries prognostic weight. Spirometry with reversibility is globally available, standardized, and reimbursable, while proposed biomarker-based replacements are not yet operational outside academic centers. The honest synthesis is therefore demotion, not deletion. BDR becomes one trait among many, not a gatekeeping test.

2. Deconstructing NOVELTY and UPLIFT

TL;DR: UPLIFT provides internal evidence that BDR is common, unstable, and nonpredictive in confirmed COPD. NOVELTY supplies the external evidence that diagnostic labels and reversibility both fail across 12,000 real-world patients, including 25% of clinically diagnosed COPD that turns out to be pre-COPD or preserved ratio impaired spirometry (PRISm).

UPLIFT, a 4-year randomized, double-blind trial of tiotropium in 5,993 patients with confirmed COPD, applied standardized pre- and postbronchodilator spirometry at every annual visit. It demonstrated three findings that demolish the diagnostic use of BDR: high prevalence of positive BDR inside confirmed COPD, within-patient instability of BDR status across annual visits, and absence of any predictive relationship between baseline BDR and tiotropium response.3

NOVELTY, a global 3-year observational cohort of approximately 12,000 patients enrolled across the asthma and COPD spectrum from both primary and specialist care, is the complementary external cohort. The principal baseline analysis showed that 23% of patients labeled as having asthma, 62% with asthma plus COPD, and 64% with COPD had postbronchodilator FEV1/FVC below the lower limit of normal.9 Treatable traits did not map onto physician-assigned labels.10 Unsupervised clustering recovered six stable clusters that crossed diagnostic labels.11 Approximately one quarter of patients diagnosed with and treated for COPD did not meet spirometric criteria, falling instead into pre-COPD or PRISm categories.12,22,23 Together, UPLIFT provides the internal evidence that BDR fails inside confirmed COPD, and NOVELTY provides the external evidence that labels and reversibility fail across the spectrum.

3. Inflammasome Biology and the Injury-Type Endotype

TL;DR NLRP3 inflammasome assembly converts cigarette smoke, particulates, and viral injury into interleukin [IL]-1β, IL-18, and gasdermin D pyroptosis, anchoring the neutrophilic and steroid-resistant phenotype. T2-high and NLRP3-driven endotypes route patients to different biologics. Dupilumab works in eosinophilic COPD; NLRP3 and IL-1 agents are in late-stage development.

The mechanistic case for replacing reversibility with endotype rests on the convergence of cigarette smoke, particulate matter, and viral injury on the NLRP3 inflammasome. Assembly requires two signals: nuclear factor (NF)-κB-driven priming that upregulates NLRP3, pro-IL-1β, and pro-IL-18, and an activation signal involving reactive oxygen species, mitochondrial dysfunction, potassium efflux, and lysosomal rupture that drives NLRP3- apoptosis‑associated speck‑like protein containing a CARD (ASC)-pro-caspase-1 assembly. Active caspase-1 cleaves IL-1β and IL-18 into mature secreted forms and cleaves gasdermin D, whose N-terminal fragment forms plasma-membrane pores that release cytokines and execute pyroptosis.16 Cigarette smoke primes and activates NLRP3 in alveolar macrophages and bronchial epithelium. In murine models, NLRP3-deficient mice and MCC950-treated wild-type mice show markedly reduced bronchoalveolar inflammation and IL-1β release.24 In humans with stable COPD, NLRP3 and IL-1β mRNA are upregulated in lung tissue, and sputum caspase-1, oligomeric ASC, IL-1β, and IL-18 rise sharply during infectious exacerbation.19,18 In severe nonatopic asthma, NLRP3 activation is associated with a neutrophilic phenotype and steroid resistance.17,28

The T2 axis defines the opposite endotype. Eosinophilic asthma and eosinophilic COPD share IL-4, IL-5, and IL-13 signaling and respond to anti-IL-5/5R and anti-IL-4Rα biologics. Dupilumab reduced exacerbations in eosinophilic COPD in the pooled BOREAS and NOTUS phase 3 trials, establishing that the endotype crosses the asthma and COPD line and that biologic eligibility should be defined by endotype, not label.20,21 NLRP3-driven and T2-low neutrophilic endotypes lack an approved targeted therapy, but selective inhibitors (dapansutrile, next-generation MCC950-class compounds) and IL-1 blockade (anakinra, canakinumab) are advancing through clinical development.25 The diagnostic implication is direct. BDR cannot distinguish T2-high eosinophilic disease from NLRP3-driven neutrophilic disease, even though they require fundamentally different therapies.

4. A Reconciled Diagnostic Algorithm

TL;DR GOLD 2025 and GINA 2024 converge on a three-layer model: postbronchodilator obstruction confirms disease, etiotype names the cause, and treatable traits with endotype direct therapy. Six sequential steps replace the legacy BDR gate. Steps 1 to 3 are feasible in primary care; steps 4 to 6 escalate to biomarker-equipped settings.

GOLD 2025 and GINA 2024 have converged on a three-layer model in which spirometry confirms obstruction, etiotype clarifies cause, and treatable traits and endotypes direct therapy. The algorithm below operationalizes this convergence. Steps 1 to 3 are feasible in primary care, while steps 4 to 6 escalate to biomarker-equipped settings.

Step 1. Symptom and exposure screen. Document chronic dyspnea, cough, sputum, recurrent wheeze, and exposure history (tobacco pack-years, biomass-hours, occupation, atopy, preterm birth, childhood respiratory events, symptom variability).

Step 2. Post-bronchodilator spirometry. Postbronchodilator FEV1/FVC less than 0.7 (or 22 Normal spirometry with symptoms and exposure documents pre-COPD.12,23 If asthma is suspected with normal spirometry, supplement with serial peak expiratory flow variability, methacholine or mannitol challenge, or a recorded reversibility measurement, documented as a trait rather than as a diagnostic gate.

Step 3. Assign provisional label. Postbronchodilator obstruction with at least 10 pack-years or biomass exposure and minimal variability is COPD; variable airflow limitation with atopy and onset typically before age 40 is asthma; combined fixed and variable disease with significant exposure is asthma and COPD overlap; PRISm and pre-COPD are documented as their own categories.

Step 4. Etiotype assignment. Apply GOLD 2023 plus taxonomy: COPD-G (genetic, with alpha-1 antitrypsin testing once for every confirmed case), COPD-D (developmental), COPD-C (cigarette), COPD-P (biomass and pollution), COPD-I (infection-related), and COPD-A (asthma-related).13,14,15 For asthma, document onset pattern, atopic status, occupational trigger, and aspirin sensitivity.

Step 5. Endotype and treatable-trait inventory. Pulmonary traits include blood eosinophils, fractional exhaled nitric oxide (FeNO), total and specific immunoglobulin E (IgE), sputum cytology where available, chronic bronchitis, bronchiectasis, emphysema pattern on CT, and persistent mucus hypersecretion.10 Extrapulmonary traits include cardiovascular disease, obesity, metabolic syndrome, anxiety and depression, osteoporosis, and frailty. Behavioral and exposure traits include active smoking, inhaler technique, adherence, and ongoing biomass or occupational exposure. Endotype inference: T2-high (blood eosinophils ≥150 to 300/µL with or without FeNO ≥25 parts per billion and with or without IgE) routes to anti-IL-5/5R, anti-IL-4Rα, anti-IgE, or anti-TSLP biologics. T2-low or NLRP3-driven (low eosinophils, frequent productive cough, frequent infectious exacerbations, neutrophilic sputum where measurable) currently has no approved targeted therapy and is managed by smoking cessation, macrolide trial, vaccination, and exacerbation prophylaxis.20,21,27

Step 6. Trait-directed treatment and reassessment. The pharmacologic core (LABA, LAMA, inhaled corticosteroids [ICS]) is selected according to the GOLD or GINA group. ICS escalation is guided by eosinophil-defined T2 trait rather than reversibility. Biologic eligibility is determined by endotype, not label. Traits should be reassessed at every exacerbation and at minimum every 6 to 12 months, recognizing that single-visit trait measurements are no more reproducible than single BDR measurements. Value comes from the pattern across visits.

5. Synthesis of the Debate

TL;DR Seven positions on one axis: from abandon BDR, through keep a modified version, to etiotype plus treatable traits plus endotype as the operational successor. The likely future is a hybrid